Skin & Regeneration
Why Different Skin Boosters Are Hard to Compare
“Skin booster” covers injectable materials such as polynucleotides (PN) and poly-D,L-lactic acid (PDLLA), rather than one standardized ingredient or procedure. Shared delivery does not imply a shared mechanism. The cited literature discusses PN and polydeoxyribonucleotide (PDRN) in relation to collagen-related processes, elasticity, and tissue hydration. It describes a PDLLA and hyaluronic acid (HA) combination through HA’s early volume and PDLLA-related collagen stimulation. These mechanisms do not predict an individual’s outcome. The sources do not directly compare the PN/PDRN and PDLLA-HA classes, so they establish neither equivalence nor a ranking.
- Rejuran names a PN injectable product; Juvelook names a PDLLA-related injectable product. Neither is an ingredient category.
- Reports describe anti-inflammatory and antioxidant properties for PN/PDRN materials. Their clinical scope and relevance to an individual remain uncertain.
- One split-face eye-area study recorded changes in skin elasticity on both the PN and non-cross-linked HA sides. That does not establish a class-wide ranking or equivalence.
- Reported risks of HA injectables include edema, bluish discoloration, and vascular occlusion. Injection site, depth, and method may matter.
- Individual material suitability and injection planning require clinical assessment.
Umbrella labels and product names
“Skin booster” is a marketing term, not an ingredient name. PN refers to a material class rather than one brand, and PDRN should not automatically be used as its synonym. PDLLA also names a material. The umbrella label does not make them interchangeable.
Shared delivery, different proposed mechanisms
PN and PDRN differ in structure and proposed pathways. The cited literature discusses collagen synthesis, skin elasticity, and tissue hydration in relation to both. It also reports anti-inflammatory and antioxidant properties. How far any of these descriptions applies clinically to an individual remains uncertain.
Studies have paired PDLLA particles with non-cross-linked HA. In that combination, HA is discussed for early volume and PDLLA for a collagen-stimulation mechanism; neither description predicts a person’s outcome.
One study cannot rank material classes
In a randomized, double-blind split-face study around the eyes, one side received PN and the other non-cross-linked HA. Both sides showed changes in skin elasticity. That eye-area result does not establish equivalence or a ranking for the material classes as a whole.
The cited sources contain no direct PN/PDRN–PDLLA-HA comparison; the PN-versus-HA study cannot fill that gap.
Reported risks with HA injectables
Reviews of HA fillers describe edema (swelling), bluish discoloration, and vascular occlusion (blocked blood flow) among possible complications. Injection site, depth, and method may affect risk. In general filler guidance, the Korean Ministry of Food and Drug Safety lists swelling, bruising, redness, pain, itching, and rash. Asan Medical Center also describes pigmentation, other skin-color changes, and problems related to vascular compression. These risks should not be erased when discussing the materials’ proposed mechanisms.
Read ingredients and study conditions separately
For a useful comparison, start with the ingredient, proposed mechanism, study area and conditions, and possible reactions. “Regeneration” alone says little about any of those. Skin condition and treatment aim also matter; a clinician must assess suitability and the injection plan.
References
- “Polydeoxyribonucleotides Improve Diabetic Wound Healing in Mouse Animal Model for Experimental Validation.” Annals of Dermatology. https://anndermatol.org/DOIx.php?id=10.5021%2Fad.2019.31.4.403
- “성형용 필러 안전사용을 위한 안내서” (in Korean). Korean Ministry of Food and Drug Safety. https://www.mfds.go.kr/brd/m_465/view.do?company_cd=&company_nm=&multi_itm_seq=0&page=1&seq=27164&srchFr=&srchTo=&srchTp=&srchWord=
- “필러 시술” (in Korean). Asan Medical Center. https://www.amc.seoul.kr/asan/healthinfo/management/managementDetail.do?managementId=539
- “Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives.” Pharmaceutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC12388916/
- “Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial.” Journal of Dermatological Treatment. https://pubmed.ncbi.nlm.nih.gov/32248707/
- “Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin.” Antioxidants. https://pmc.ncbi.nlm.nih.gov/articles/PMC10294940/
- “Complications of Periorbital Cosmetic Hyaluronic Acid Filler Injections: A Major Review.” Turkish Journal of Ophthalmology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12559836/
- “Bridging a Century-Old Problem: The Pathophysiology and Molecular Mechanisms of HA Filler-Induced Vascular Occlusion (FIVO)—Implications for Therapeutic Interventions.” Molecules. https://pmc.ncbi.nlm.nih.gov/articles/PMC9458226/
- Beyond Clinic YouTube video (in Korean), uploaded August 26, 2026. https://www.youtube.com/watch?v=R2lEZvpPQ4Y
Frequently asked questions
Do PN/PDRN and PDLLA-HA combinations work in the same way?
No. The cited literature discusses polynucleotide (PN) and polydeoxyribonucleotide (PDRN) in relation to collagen-related processes and tissue hydration, while a poly-D,L-lactic acid (PDLLA) and hyaluronic acid (HA) combination is described in terms of early HA volume and PDLLA-related collagen stimulation. A proposed mechanism does not predict an individual's result, and PN and PDRN should not be treated as identical.
If both sides changed in the eye-area study, does that prove the material classes are equivalent?
No. That split-face study compared a PN injectable with non-cross-linked HA around the eyes and recorded changes on both sides. It did not compare PN/PDRN as a class with PDLLA-HA combinations as a class. A finding in one area and set of conditions cannot establish class-wide equivalence or a ranking.
Do reported anti-inflammatory and antioxidant properties apply to everyone?
No. Such properties have been reported for PN/PDRN materials, but a reported mechanism or property does not establish how far it applies clinically or what any one person can expect.
How is an injectable material chosen?
The material's proposed mechanism is only one consideration. Skin condition, the treatment aim, injection site and method, and possible reactions also matter. Individual suitability and an injection plan require clinical assessment.